Cantor Fitzgerald restated their buy rating on shares of Axsome Therapeutics Inc. (NASDAQ:AXSM) in a research note released on Tuesday morning. The firm currently has a $13.00 price target on the stock.

AXSM has been the subject of several other research reports. Zacks Investment Research lowered shares of Axsome Therapeutics from a hold rating to a sell rating in a research note on Tuesday, October 11th. Brean Capital reaffirmed a buy rating on shares of Axsome Therapeutics in a report on Wednesday, August 10th.

Axsome Therapeutics (NASDAQ:AXSM) opened at 7.65 on Tuesday. The stock’s 50 day moving average is $7.34 and its 200 day moving average is $7.87. The firm’s market capitalization is $146.49 million. Axsome Therapeutics has a one year low of $5.37 and a one year high of $15.74.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC purchased a new position in shares of Axsome Therapeutics during the third quarter valued at approximately $104,000. Baldwin Brothers Inc. MA purchased a new position in shares of Axsome Therapeutics during the third quarter valued at approximately $119,000. Teachers Advisors Inc. purchased a new position in shares of Axsome Therapeutics during the second quarter valued at approximately $128,000. Schwab Charles Investment Management Inc. purchased a new position in shares of Axsome Therapeutics during the second quarter valued at approximately $134,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Axsome Therapeutics during the second quarter valued at approximately $161,000. 30.51% of the stock is owned by hedge funds and other institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.

5 Day Chart for NASDAQ:AXSM

Receive News & Stock Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related stocks with our FREE daily email newsletter.